624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance

• Rupal Bhatt,
• Ana Lako,
• Benjamin Chen,
• Daniel Tenney,
• Sharmila Chamling Rai,
• Piali Mukherjee,
• Brendan O’Brien,
• Sonia Dolfi

Affiliations

Rupal Bhatt

1BIDMC, Boston, MA, USA

Ana Lako

1Bristol Myers Squibb, Lawrenceville, NJ, USA

Benjamin Chen

Bristol-Myers Squibb, Cambridge, MA, USA

Daniel Tenney

12Bristol Myers Squibb, Princeton, NJ, USA

Sharmila Chamling Rai

2Bristol Myers Squibb, Cambridge, MA, USA

Piali Mukherjee

2Bristol Myers Squibb, Cambridge, MA, USA

Brendan O’Brien

2Bristol Myers Squibb, Cambridge, MA, USA

Sonia Dolfi

3Bristol Myers Squibb, Princeton, NJ, USA